TauRx Therapeutics Ltd.

Pharmaceutical company co-founded in 2002 by Prof. Claude Wischik of University of Aberdeen, with main operations in Aberdeen, Scotland. Pioneer in developing protein aggregation inhibitors targeting tau for Alzheimer's treatment. Lead compound HMTM (Hydromethylthionine mesylate) was submitted to MHRA for marketing authorisation in 2024 as a potential first oral disease-modifying treatment for Alzheimer's disease worldwide. Received MHRA ILAP designation.